MULTIPLE MYELOMA

This study looks at whether plasma exchange or newer drugs like daratumumab can help the kidneys recover in people with multiple myeloma who have a type of kidney damage called light chain cast nephropathy. About 450 adults with this condition will be followed for 90 days to see …

This early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to see if t…

This study tests a new combination of two drugs, etentamig and iberdomide, in adults with multiple myeloma that has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combo can control the cancer. About 135 participants will take part at s…

This study tests whether the drug selinexor can safely extend the benefits of CAR-T cell therapy in people with high-risk multiple myeloma that has returned after other treatments. About 20 participants will take selinexor pills after their CAR-T infusion. The goal is to see if t…

This study tests whether adding the drug teclistamab to standard maintenance therapy (lenalidomide) can help keep multiple myeloma from coming back after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment will b…

This study tests a new drug called linvoseltamab in people with multiple myeloma that has returned or stopped responding to other treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink or control the cancer. About 387 participants wil…

This study tests a combination of three drugs (carfilzomib, iberdomide, and dexamethasone) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment is safe and effective at reducing cancer before transplant.…

This phase 3 trial tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will participate. The goal is to see if …

This study is for people with multiple myeloma whose cancer remains active after CAR-T cell therapy. It tests whether adding targeted radiation to remaining tumors can improve outcomes. About 30 participants will receive low-dose radiation to up to five tumor sites. The goal is t…

This study tests whether adding cevostamab to standard drugs (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults who have already tried 1-3 prior therapies will take part. The goal is to see if the new combination can make …

This early study tests a new pill, mezigdomide, given after CAR T-cell therapy (Abecma) in 15 adults with multiple myeloma that has returned. The goal is to see if the drug is safe and can help the CAR T cells last longer to better control the cancer. Participants must have tried…

This study looks at whether people with relapsed multiple myeloma can safely give themselves the drug elranatamab at home instead of going to the clinic. About 20 participants will track side effects, time spent, and quality of life. The goal is to see if home treatment is safe, …

This early-phase study tests a new way to prepare the body for CAR T-cell therapy in people with multiple myeloma who also have kidney problems. Standard prep can be hard on the kidneys, so researchers are using low-dose radiation plus a chemotherapy drug instead. The goal is to …

This study tests whether adding elranatamab to standard drugs (lenalidomide and dexamethasone) can deeply reduce cancer cells in people newly diagnosed with multiple myeloma. About 104 participants will receive the combination and be monitored for minimal residual disease (MRD) a…

This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can help control multiple myeloma that has returned or not responded to treatment. About 49 adults who have already received at least 4 prior treatments, including a CAR-T cell therapy called idec…

This early-phase study tests a drug called carfilzomib combined with standard chemotherapy to see if it helps collect more stem cells for transplant in people with multiple myeloma. The main goals are to find the safest dose and check for side effects. About 18 participants will …

This study is for people with multiple myeloma, a type of blood cancer, that has returned or no longer responds to standard treatments. Researchers are testing a new drug, CC-92480, combined with other therapies to see if it is safe and can shrink tumors. About 260 participants w…

This study tests a new treatment called arlocabtagene autoleucel (BMS-986393) for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses a patient's own immune cells, modified to target cancer cells. The goal is to see if it can sh…

This program provides early access to the investigational drug selinexor for people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of standard treatments and cannot join a clinical trial. Patients must get approval from their doctor and local regulato…

This study tests a new drug, enzomenib, in adults with acute leukemia and other blood cancers that have come back or not improved with standard treatments. The goal is to find a safe dose and see if the drug can shrink or control the cancer. About 606 people will take part in thi…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This study tests a personalized approach for people with newly diagnosed multiple myeloma who have had a stem cell transplant. After transplant, participants receive the drug elranatamab as maintenance therapy, with the dose and duration guided by a sensitive blood test (MRD test…

This early-stage trial tests a new type of CAR T cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses immune cells engineered to recognize and attack myeloma cells. The main goals are to see if the treatment …

This study tests whether two different drug combinations (teclistamab with daratumumab or talquetamab with daratumumab) can delay the start of multiple myeloma in people with high-risk smoldering myeloma. About 50 participants will receive treatment and be monitored for side effe…

This study tests a proactive health program called PASCA for adults aged 18 to 70 with multiple myeloma who have had a stem cell transplant. The program screens for seven common complications—like high blood pressure, kidney problems, chronic pain, and fatigue—and quickly connect…

This study is for adults with multiple myeloma that has returned or stopped responding to treatment. Researchers want to see if giving the drug belantamab mafodotin less often, combined with other standard cancer medicines, can still control the cancer while causing fewer eye pro…

This study looks at whether a structured exercise program can help older adults who have survived blood cancers like leukemia or lymphoma slow down the aging process. Researchers want to see if participants can stick with the exercise plan and if it improves their physical functi…

This study tests a combination of four drugs (bortezomib, isatuximab, cyclophosphamide, and dexamethasone) as an initial treatment for multiple myeloma patients who also have kidney problems and are eligible for a stem cell transplant. The goal is to see if this drug mix can redu…

This study tests two different drug combinations to prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body after a stem cell transplant. About 400 adults with blood cancers like leukemia or lymphoma will receive either thymogl…

This study tests a new combination of drugs (iberdomide, bortezomib, dexamethasone, and isatuximab) for people aged 65 and older who have just been diagnosed with multiple myeloma and cannot have a stem cell transplant. The goal is to see how well the treatment controls the disea…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This study tests a combination of two drugs, teclistamab and daratumumab (Tec-Dara), in 30 adults newly diagnosed with multiple myeloma and a related condition called AL amyloidosis. The goal is to see if the combo can keep the disease from getting worse for at least a year, and …

This early-stage study tests a new drug called ABBV-438 in about 127 adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the dr…

This study is for people with multiple myeloma that has come back or not responded to at least three prior treatments. It tests a new cell therapy (arlocabtagene autoleucel) given together with other drugs to find safe and effective doses. The goal is to control the cancer, not c…

This study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…

This study offers ongoing access to the drug elranatamab for people with multiple myeloma who were already benefiting from it in earlier Pfizer studies. The goal is to keep providing the treatment while monitoring for any side effects. About 80 participants will take part, and th…

This study tests a personalized treatment plan for people aged 65 and older with newly diagnosed multiple myeloma. The treatment is adjusted based on each patient's frailty level to improve effectiveness and reduce side effects. About 131 participants will receive a combination o…

This study tests a new treatment called BMS-986453 for people recently diagnosed with multiple myeloma who are not planning a stem cell transplant. The treatment uses specially engineered immune cells to target and attack myeloma cells. The goal is to see if it is safe and helps …

This study tests whether a combination of two drugs, isatuximab and lenalidomide, can eliminate remaining cancer cells in multiple myeloma patients after a stem cell transplant. About 50 adults whose cancer is still detectable after transplant will receive this maintenance therap…

This study tests a new type of CAR-T cell therapy for people with multiple myeloma who also have kidney problems. The treatment uses the patient's own immune cells, modified to target and attack myeloma cells. The goal is to see if this therapy can control the disease and prevent…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants will receive the drug alone or with other treatments.

This study tests whether a medicine called IgPro20 can help prevent infections in people with multiple myeloma who have low antibody levels due to their cancer treatment. About 100 participants will either receive IgPro20 or standard care. The goal is to see if the drug reduces i…

This early-phase study tests whether collecting a patient's own blood stem cells and giving them alongside CAR-T cell therapy is safe and doable for people with blood cancers that have come back or not responded to treatment. About 20 adults with cancers like lymphoma, leukemia, …

This study is for people with a specific genetic type of multiple myeloma (t(11;14)) that has come back or stopped responding to treatment. It tests a combination of two drugs, belantamab mafodotin and venetoclax, sometimes with a steroid. The goal is to find the safest and most …

This study tests a new drug called cevostamab in 20 Chinese patients whose multiple myeloma has come back or stopped responding to treatment. The goal is to see how the drug moves through the body, if it is safe, and whether it can shrink the cancer. Patients will receive the dru…

This early-phase study tests a new CAR-T cell therapy (WS-CART-CS1) that targets the CS1 protein on multiple myeloma cells. It is for patients whose cancer has returned or not responded to at least three prior treatments. The main goals are to check safety and see if the therapy …

This study is for people newly diagnosed with multiple myeloma. It uses a sensitive test to measure leftover cancer cells (minimal residual disease, or MRD) after initial treatment. For those with very low MRD, the study tests if three extra cycles of drugs can replace a stem cel…

This program offers early access to venetoclax for people with certain blood cancers like chronic lymphocytic leukemia, multiple myeloma, or acute myeloid leukemia, before the drug is fully approved in their region. It is for patients who have no other suitable treatment options …

This study tests whether a new drug called elranatamab, alone or with another drug (daratumumab), works better than a standard three-drug combination for people with multiple myeloma that came back or didn't respond after at least one prior treatment. About 944 adults will be ran…

This study tests whether giving a targeted therapy drug that matches a specific gene change in a person's cancer can shrink tumors or stop them from growing. It includes adults with advanced solid tumors, multiple myeloma, or certain lymphomas who have no standard treatment optio…

This study tests an experimental drug, etentamig, for adults with multiple myeloma, a blood cancer that often returns or resists treatment. About 440 participants worldwide will receive etentamig alone or combined with other cancer drugs to find safe doses and check if it shrinks…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to better attack tumor mutations, and infuse them back. The goal is to s…

This early-phase study tests whether giving sirolimus before standard bispecific antibody therapy can improve T-cell function and treatment response in people with multiple myeloma. About 10 participants will receive sirolimus first, then the antibody treatment. The main goals ar…

This study tests a new drug called etentamig combined with daratumumab against a standard treatment for multiple myeloma, a blood cancer. It is for people newly diagnosed who cannot have a stem cell transplant. About 660 adults worldwide will join, and researchers will check how …

This study tests whether adding a vitamin A derivative (ATRA) to a standard drug combination (carfilzomib and dexamethasone) can make multiple myeloma respond again in patients whose cancer has stopped responding to carfilzomib. About 42 adults with relapsed or refractory myeloma…

This study tests whether adding linvoseltamab to standard lenalidomide maintenance therapy can eliminate remaining cancer cells in people with multiple myeloma. It includes two groups: those with residual disease after initial treatment and those whose disease has returned. The g…

This study tests a three-drug combination (isatuximab, lenalidomide, dexamethasone) at lower-than-standard doses in 50 people newly diagnosed with multiple myeloma who are at high risk for side effects. The goal is to see if the lower doses can still control the cancer while redu…

This phase 3 study tests whether a new combination of drugs (belantamab mafodotin, lenalidomide, and dexamethasone) can keep multiple myeloma from coming back longer than the current standard treatment. About 520 adults newly diagnosed with multiple myeloma who cannot have a stem…

This study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after treatment with idecabtagene vicleucel (a CAR T-cell therapy). About 32 adults with relapsed or refractory myeloma will receive elranatamab as a consolidation step. The goal is t…

This early-stage trial tests adding venetoclax to three different standard drug combinations for people with a specific genetic subtype of multiple myeloma (t(11;14)). The goal is to find the safest dose and see if the combination can better control the cancer. About 100 particip…

This study tests whether a drug called NT-I7 can help CAR-T cells stay active longer in people with multiple myeloma that has come back or not responded to treatment. About 52 participants will receive either NT-I7 or a placebo after standard CAR-T therapy. The goal is to see if …

This study tests a drug called belantamab, alone or with other treatments, in people with multiple myeloma (a type of blood cancer). It is for patients whose cancer has come back or not responded to prior therapies. The goal is to find safe doses and see if the drug shrinks tumor…

This study tests a new treatment called GC012F for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. GC012F is a type of cell therapy that reprograms a patient's own immune cells to attack two targets (CD19 and BCMA) on myelom…

This study tests a combination of four drugs (cyclophosphamide, bortezomib, dexamethasone, and daratumumab) in 20 adults with kidney disease caused by abnormal proteins from a blood condition. The goal is to see if the treatment is safe and can improve kidney function. This is a …

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This study is for people newly diagnosed with multiple myeloma or amyloidosis. It tests whether a very sensitive genetic test can identify patients who respond so well to initial drug therapy that they can safely postpone a stem cell transplant. The goal is to see if avoiding or …

This study tests a new combination of drugs (epunamin plus DECP) for people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if this combo can shrink tumors or slow the disease. About 48 adults aged 18-75 will take part, and the study wil…

This study tests if the drug elranatamab, given before and after a stem cell transplant, can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk disease will receive the drug to reduce cancer cells before transplant and then as maintenance t…

This early-stage study tests a new type of CAR T-cell therapy for adults with certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to target an…

This early-phase study tests whether a new type of CAR-T cell therapy, which targets two proteins (CD19 and BCMA) on myeloma cells, is safe for people whose cancer has returned or stopped responding to treatment. Nine participants will receive the therapy and be monitored for sid…

This study is for people with multiple myeloma that has come back or stopped responding to treatment. It tests whether adding a chemotherapy drug (cyclophosphamide) to an immunotherapy (elranatamab) works better than the immunotherapy alone. About 26 adults with certain risk fact…

This study looks at whether CAR T cell therapy can be safely given to people with blood cancers (like lymphoma, myeloma, or leukemia) who also have moderate to severe kidney problems. Doctors will adjust the standard chemotherapy given before the CAR T cells to reduce side effect…

This study tests new combinations of drugs (teclistamab, talquetamab, and JNJ-79635322) in 160 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and work better than standard treatments. Par…

This study tests whether a new drug called GR1803 works better than the standard combination of daratumumab, pomalidomide, and dexamethasone (DPd) for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior treatments. About 358 adults with this b…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with rare cancers that have a specific BRAF V600 mutation. About 30 people with various cancer types will receive the combination to see if it shrinks tumors or prevents growth for a…

This study looks at whether a specific diet can improve how well treatment works and how patients feel. About 220 people with newly diagnosed multiple myeloma will take part. Researchers will track treatment response and quality of life through questionnaires and medical tests.

This early study tests a new treatment called KSVCBD injection for people with multiple myeloma that has come back or not responded to other therapies. The treatment uses specially engineered immune cells (CAR-T cells) to find and attack cancer cells. The main goals are to check …

This study tests if the antiviral drug remdesivir can safely treat RSV (a common respiratory virus) in 60 adults whose immune systems are weakened by cancer treatments or autoimmune therapies. Participants must have a confirmed RSV infection with symptoms. The main goal is to see…

This study tests whether a new drug combination (elranatamab, daratumumab, and lenalidomide) works better than a standard combination for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The trial involves about 1,116 participants and …

This early-stage study tests a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to check the safety and find the right dose of this…

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a bone marrow transplant in people with multiple myeloma. About 60 Chinese adults with active myeloma will receive either the drug combo or a placebo before stem cell collection. The…

This early-stage study is testing whether combining two drugs, teclistamab and mezigdomide, is safe and works for people with multiple myeloma that has returned or not responded to prior treatments. About 18 participants will receive the combination to see how well it controls th…

This early-phase study tests a new therapy using a patient's own immune cells (T cells) trained to attack proteins found on myeloma cells. It includes adults with multiple myeloma, high-risk MGUS, or smoldering myeloma. The main goals are to find a safe dose and understand side e…

This study tests an experimental drug called linvoseltamab in people with newly diagnosed multiple myeloma, a type of blood cancer. The drug aims to shrink tumors by helping the immune system attack cancer cells. About 149 participants will join, including those who can or cannot…

This study tests whether adding targeted radiation to the drug talquetamab can safely and effectively treat multiple myeloma that has spread to organs or soft tissues (extramedullary disease). About 20 adults with this hard-to-treat condition will receive radiation to one tumor s…

This study tests whether taking prebiotics (a type of fiber) before and after a stem cell transplant can improve gut bacteria diversity in people with multiple myeloma or lymphoma. About 30 participants will receive either prebiotics or a placebo mixed into food. The goal is to s…

This study tests whether giving immune globulin infusions regularly from the start can prevent serious infections in adults with multiple myeloma who are receiving a type of immunotherapy called bispecific antibody therapy. About 183 participants will be randomly assigned to rece…

This study tests whether two new drug combinations (Tal-P and Tal-Tec) work better than current standard treatments for multiple myeloma, a type of blood cancer. About 795 adults with multiple myeloma will be randomly assigned to one of the treatment groups. The main goal is to s…

This study tests the safety of a drug called teclistamab in 75 Indian adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. Participants receive teclistamab alone, and researchers monitor for side effects and how well the cancer…

This program offers a special type of cell therapy (ide-cel) to people with multiple myeloma whose manufactured treatment batch didn't meet commercial standards but may still be safe and effective. Participants must be clinically stable and have no other suitable treatment option…

This study tests a new drug, JNJ-79635322, against another drug called teclistamab in people with multiple myeloma that has come back or not responded after 1 to 3 prior treatments. About 700 adults will take part to see which drug works better at shrinking tumors and delaying th…

This study looks at a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned after their first treatment. About 50 adults will take part to see if this combo helps keep the cancer away longer than other options. Th…

This study tests a new cancer treatment called cilta-cel for people with multiple myeloma, a type of blood cancer. The goal is to see if a modified chemotherapy preparation can make the treatment work better and be safer. About 60 participants will receive the therapy and be moni…

This study follows about 75 people with multiple myeloma who also have a weakened immune system (secondary immunodeficiency) and are receiving the drug HyQvia as part of their normal care. Researchers will collect information on how the drug is given, such as dose, infusion speed…

This study tests a new medicine called AZD0305 in people with multiple myeloma, a type of blood cancer. The goal is to find safe doses and see if it works better when used alone or with other cancer drugs. About 226 adults will take part, and researchers will monitor side effects…

This study tests two drug combinations (teclistamab plus daratumumab or lenalidomide) in people aged 65 and older with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if these combinations are safe and can achieve a very good partial re…

This early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy can safely improve outcomes for people with multiple myeloma that has returned or not responded to treatment. About 25 adults will receive the vaccine along wit…

This study tests whether adding isatuximab to the standard drug lenalidomide can better control high-risk multiple myeloma after a stem cell transplant. About 61 adults aged 18 to 72 with newly diagnosed high-risk myeloma will receive the combination as maintenance therapy. The m…

This study tests whether adding the experimental drug linvoseltamab after initial standard therapy works better than continuing standard therapy alone for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 1,000 participants will be randoml…

This early-phase trial tests a new treatment for multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in the lab using CRISPR gene editing to recognize and attack cancer cells. Abou…

This study tests a new treatment called anitocabtagene autoleucel (a type of cell therapy) against standard treatments for people with multiple myeloma that has returned or not responded to 1-3 prior therapies. About 450 participants will be randomly assigned to receive either th…

This study is for people with serious blood cancers, immune deficiencies, or genetic disorders who need a stem cell transplant. Researchers are using umbilical cord blood from unrelated donors to see how well the new cells take hold and rebuild healthy blood counts. The goal is t…

This phase 2 study tests whether two drugs, teclistamab and talquetamab, can be given safely in an outpatient clinic instead of requiring a hospital stay for people with multiple myeloma. About 100 adults who have already tried other treatments will receive preventive medicines t…

This early-phase trial tests a combination of three drugs—talquetamab, iberdomide, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and check for side effects. About 32 adults will t…

This early-phase study tests an experimental pill called KTX-1001 in adults with multiple myeloma whose cancer has come back or stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the disease. About 165 pa…

This study is testing a new combination of two drugs, mezigdomide and elranatamab, in about 62 adults with multiple myeloma that has returned or no longer responds to standard treatments. The main goals are to find the best dose and check for side effects. Researchers will also l…

This study tests a two-step stem cell transplant using lower doses of radiation and chemo before the transplant. The goal is to reduce deaths from the transplant itself while still treating blood cancers like leukemia and lymphoma. About 63 adults will take part. If successful, t…

This study tests whether the drug talquetamab can help people with multiple myeloma who have already received a type of immunotherapy called BCMA CAR T-cell therapy. The goal is to see if adding talquetamab improves response and keeps the cancer from coming back. About 17 adults …

This study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely in an outpatient setting instead of the hospital. It involves 15 patients who have tried at least three prior treatments. The goal is to develop clear procedures for outp…

This early-phase study tests a new type of CAR-T cell therapy that targets two cancer markers (BCMA and GPRC5D) as a first treatment for people with high-risk multiple myeloma or plasmacytoma. About 20 participants will receive the therapy to see if it is safe and effective, and …

This study tests whether switching between two different drug combinations (Dara-RVd and Tec-RVd) is safe and effective for people newly diagnosed with multiple myeloma. About 65 participants will receive alternating cycles of these therapies. The goal is to achieve undetectable …

This study tests a new medicine called elranatamab (given as a weekly shot) against standard drug combinations for multiple myeloma that has returned or stopped responding to previous treatments. About 492 adults aged 18 and older who have already tried at least one prior therapy…

This study tests whether a two-step immunotherapy approach can eliminate remaining cancer cells in people with newly diagnosed multiple myeloma who still have detectable disease after standard treatment. Participants first receive talquetamab, and if that doesn't clear the cancer…

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see how many patients respond to the therapy. This is n…

This study tests two new drug combinations (Tec-DR and Tal-DR) against a standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if the new combos keep the cancer from growing longer and help more patients ach…

This study tests a new approach to collecting stem cells for people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma who need a stem cell transplant. The goal is to see if using a standard drug alone, and adding another drug only when needed, can collect enough st…

This study tests a combination of four drugs (daratumumab, carfilzomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients achieve tumor shrinkage and how long the benefit …

This early-phase study tests a new drug called SHR-3836 in 99 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors. Parti…

This early-stage study tests a new drug called BL-M24D1 in about 33 adults with multiple myeloma or other blood cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug helps control the disease. Particip…

This study is for older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. It compares taking the antibody drugs daratumumab or isatuximab continuously versus stopping after about 18 months. The goal is to see if the shorter treatment works just …

This study tests an experimental drug called surzetoclax in people with multiple myeloma that has returned or stopped responding to other treatments. The drug is given alone or with standard therapies to find the best dose and check safety. About 130 adults will take part worldwi…

This study tests whether giving specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, is safe and can help control relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and multiple myeloma. About 80 participants will receive …

This study tests a four-cycle treatment of daratumumab combined with three other drugs (Dara-CyBorD) in 30 people newly diagnosed with multiple myeloma who also have kidney failure. The goal is to see how well the treatment shrinks the cancer and improves kidney function. The stu…

This study tests if a new drug, iberdomide, works better than the current standard lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer pr…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has returned or not responded to standard therapies. About 18 adults will receive the therapy along with two chemotherapy drugs to prepare the body. The main goal is to c…

This early-stage trial tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a blood cancer. About 140 adults with myeloma will receive different drug combinations to find the safest and most effective doses. The goal is to control the disease an…

This study tests an experimental drug called JNJ-79635322 in people with multiple myeloma that has come back or stopped responding to treatment. Participants must have already tried at least three different types of therapy. The main goal is to see how well the drug shrinks or co…

This study looks at whether people with multiple myeloma who have been in a very deep remission (called MRD-negative) for at least two years can safely stop their maintenance therapy. Researchers will follow 70 participants for up to 24 months to see how many remain in remission …

This study tests a new drug, JNJ-79635322, against another antibody treatment in people with multiple myeloma that has come back or stopped responding after at least three prior treatments. About 400 participants will be randomly assigned to one of the two treatments. The goal is…

This study is for people whose multiple myeloma has returned or stopped responding to standard treatments, including CAR T-cell therapy. Researchers are testing a combination of four drugs (belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone) to see if it can shrin…

This study tests a drug called elranatamab in 33 people with multiple myeloma that has returned or not responded after 1 to 3 prior treatments. The goal is to see if the drug can make cancer cells undetectable in tests. Participants will receive elranatamab alone, and the study w…

This early-phase study tests whether a personalized cancer vaccine (made from a patient's own cells) combined with the drug elranatamab is safe and feasible for people with multiple myeloma that has returned or not responded to prior treatments. Up to 25 adults with at least thre…

This study tests an experimental pill called LP-118 in up to 100 adults with blood cancers that have come back or not responded to treatment. The main goal is to find a safe dose and see how the body processes the drug. Early signs of effectiveness will also be tracked, but this …

This program offers a special cell therapy called cilta-cel to people with multiple myeloma who have run out of standard options. The treatment is made from the patient's own immune cells and is given when other therapies are not possible. It is only for those with serious or lif…

This study is for people with multiple myeloma who have been on maintenance therapy for at least two years after a stem cell transplant and have no detectable cancer (minimal residual disease negative). The goal is to see if it's safe to stop maintenance drugs without the cancer …

This early-phase trial tests a new treatment called AZD0120 for adults with multiple myeloma, a type of blood cancer. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and CD19). The main goals are to check safety and find the right dose, …

This study is for people with multiple myeloma that has come back or stopped responding to other treatments. The trial has two parts: first, finding the best dose of a drug called belumosudil mesylate, and second, testing that dose alone or with dexamethasone to see if it can con…

This study tests a combination of a stem cell transplant and a special immune cell therapy (C-CAR088) for people with a very aggressive form of multiple myeloma that didn't respond well to initial treatment. The goal is to see if this two-step approach is safe and can better cont…

This study is for people with high-risk multiple myeloma who have completed initial treatment. It compares two maintenance therapies: a combination of ixazomib plus a reduced dose of lenalidomide versus ixazomib alone. The goal is to see which approach better delays cancer progre…

This study is for people over 60 with multiple myeloma who are getting a stem cell transplant as part of their treatment. Researchers want to see if giving a drug called siltuximab along with a personalized dose of chemotherapy (melphalan) works better than the standard dosing me…

This early-phase study tests a new cell therapy called LVIVO-TaVec200 in 36 adults with multiple myeloma that has returned or not responded to standard treatments. The goal is to check if the therapy is safe, find the right dose, and see how long the modified cells stay in the bo…

This study tests an experimental drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that came back after prior therapy. The main goal is to see if the combinations are safe and find the right doses. About 317 adults with this blood ca…

This study offers ongoing treatment with daratumumab for up to 500 adults with multiple myeloma who are already benefiting from it in earlier studies. The goal is to keep providing the drug while monitoring long-term safety, such as serious side effects and infections. Participan…

This early-stage study tests a new drug called TQB2934 for people with multiple myeloma, a type of blood cancer. The drug is designed to help the body's immune cells find and kill cancer cells. About 42 adults aged 18 to 75 will receive the drug as a shot under the skin to check …

This early-phase study tests a new injection called JY232 in 9 people with multiple myeloma that has returned or not responded to prior treatments. The main goals are to check safety and find the best dose. Researchers will also see if the treatment helps shrink the cancer. This …

This study tests a new treatment called BCMA-CART, with or without a stem cell transplant, in young adults (18-55) newly diagnosed with multiple myeloma. The goal is to see if it can make the cancer disappear (MRD negative) and keep it away longer. About 50 people will join this …

This early-phase study tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. About 138 adults with the disease will take part to see how the drug works in the body and if it he…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests a new imaging agent called 68Ga-NB381 that targets a protein (CD38) found on multiple myeloma cancer cells. The goal is to see if it can detect the disease more accurately than current scans, potentially reducing the need for invasive bone marrow biopsies. About …

This study is testing a new blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will enroll 7,000 people to see if the test can find cancer early, detect any cancer left after treatment, and spot a relapse before …

This early-stage study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans to find multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the tracer and have a PET scan. The goal is to see if this met…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This study aims to find multiple myeloma at its earliest, precancerous stage (MGUS) in people at higher risk, including Black adults and close relatives of patients with plasma cell disorders. Researchers will screen up to 1,665 volunteers with a simple blood test. The goal is to…

This study looks at why people with multiple myeloma fall and tests a home exercise program to prevent falls. About 60 adults on cancer therapy will use a training app for 24 weeks. The goal is to see if the program is easy to follow and reduces fear of falling.

This study compares two common steroids, methylprednisolone and dexamethasone, to see which is better at preventing allergic reactions to the drug motixafortide in multiple myeloma patients. Motixafortide helps collect stem cells for transplant, but often causes reactions. The go…

This study is testing whether a home-based program combining gentle mindfulness exercises, physical activity, and telephone health coaching can reduce fatigue and improve quality of life in people aged 65 and older with multiple myeloma. Participants will use a remote monitoring …

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers. The goal is to see if home treatment is preferred and just as safe. Participants will receive their usual cancer drugs at home from a specialized team, and researchers will …

This study tests whether a specific lighting schedule can help multiple myeloma patients undergoing their first stem cell transplant. Two hundred participants will receive either a special light treatment or standard light, and researchers will measure sleep quality, inflammation…

This study looks at whether a personalized website can help people with multiple myeloma manage treatment side effects and improve their quality of life. About 108 adults with newly diagnosed or returning myeloma will use the platform to report symptoms and get tailored education…

This study tests if a shorter course of radiation (hypofractionation) is safe for people with multiple myeloma who need pelvic radiation. Instead of the usual 2-3 weeks, the radiation is given over fewer days with slightly higher daily doses. The goal is to find the highest safe …

This study tests whether a geriatric assessment—a thorough check of physical function, thinking skills, and nutrition—can guide extra support to help adults aged 60 and older recover faster after CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. Participants will…

This study tests a 'go-slow' treatment plan for ultra-frail patients newly diagnosed with multiple myeloma. Instead of starting all drugs at once, patients first receive two medications (isatuximab and dexamethasone) and then add a third (lenalidomide) after two cycles. The goal …

This study looks at whether adding early palliative care to standard treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will be randomly assigned to receive either usual care alone or usual care plus ear…

This study tests whether a medication called budesonide can prevent severe diarrhea in people with multiple myeloma who are receiving a stem cell transplant. About 120 adults will be randomly assigned to get either budesonide or a placebo alongside standard care. The goal is to s…

This study looks at whether a diet that includes longer overnight fasting and follows a Mediterranean eating pattern is possible for people with multiple myeloma or its early forms (MGUS and smoldering myeloma). Researchers will check how many people agree to join, stick with the…

This study tests a personalized exercise program for 120 multiple myeloma patients who are about to receive a stem cell transplant. The goal is to see if the program reduces fatigue and improves quality of life. Patients will follow an adapted physical activity plan designed to b…

This study tests whether a prehabilitation (pre-transplant exercise) program can help older adults (60+) with multiple myeloma maintain or improve physical function before and after a stem cell transplant. About 30 participants will be randomly assigned to either the exercise pro…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their thera…

This study tests whether an 8-week home exercise program, done before a stem cell transplant, can improve muscle strength and physical fitness in people with multiple myeloma. Thirty participants will either exercise or continue normal activities. The goal is to see if pre-transp…

This study tests whether adding a non-opioid painkiller (ketorolac) to standard opioid painkillers can reduce the amount of opioids needed after preventive leg surgery. The surgery is done in cancer patients with bone lesions to prevent fractures. About 60 adults will be randomly…

This study tests whether a combination of three drugs (fosaprepitant, tropisetron, and olanzapine) works better than the standard treatment to prevent delayed nausea and vomiting after high-dose chemotherapy in people with multiple myeloma undergoing a stem cell transplant. About…

This study tests if certain preventive treatments can reduce or prevent taste changes (dysgeusia) caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of…

This early-phase study tests whether loratadine, a common allergy medication, can reduce bone pain caused by the drug G-CSF in multiple myeloma patients undergoing stem cell collection. Researchers will compare pain levels between groups using a standard pain scale. The trial aim…

This study looks at whether adding a special palliative care program (called PEACE) to usual cancer care can improve quality of life for adults with blood cancers like lymphoma, leukemia, or multiple myeloma who are receiving cell therapy. About 90 participants will be randomly a…

This study looks at whether people with multiple myeloma can and want to join a special exercise program while getting chemotherapy before a stem cell transplant. The program includes both in-person and online sessions to help keep up physical fitness, muscle strength, and qualit…

This study interviews 75 adults with advanced cancers (like breast, lung, or leukemia) who are taking long-term targeted treatments. Researchers want to understand their experiences and challenges to find better ways to support them. No new treatments are tested—this is about imp…

This study aims to collect information from cancer patients about their symptoms and experiences during treatment, using weekly online surveys. The goal is to build a database that helps doctors better understand and manage side effects. About 25 adults with breast, lung, ovarian…

This study follows 2000 people with multiple myeloma in the West-Occitanie region of France to see what treatments they actually receive and how those treatments affect their disease and daily life. Researchers want to fill the gap between strict clinical trials and real-world ca…

This study looks at whether CAR-T cell therapy, a new immune treatment for blood cancers, can cause early heart problems. About 60 adults who just received CAR-T cells will get heart ultrasounds before and a few days after treatment. The goal is to measure how often heart functio…

This study is looking for 2,000 people who have a close family member with a blood cancer like multiple myeloma. The goal is to find early warning signs of the disease by collecting blood samples and health information over time. Participants will not receive any treatment, but t…

This study tests whether a monthly monitoring program (ICOPE) can help detect early signs of decline in people over 70 with multiple myeloma. The goal is to prevent loss of independence. About 30 participants will use a digital app or chatbot for one year to track their health.

This study is a large registry that will follow 2200 people with multiple myeloma in Germany. Its goal is to collect information on the types of treatments patients actually receive, how well they work, and how patients feel over time. Participants will provide medical data and o…

This study follows about 295 people with multiple myeloma who have already received the CAR-T therapy cilta-cel. The goal is to watch for any delayed side effects, such as new cancers, nerve problems, or serious infections. Participants will have regular check-ups over several ye…

This study collects tissue and fluid samples (like blood, urine, or tumor biopsies) from up to 5,000 children and adults with cancer. The samples are used for research only, not for direct treatment. The goal is to help scientists better understand cancer and develop new tests or…

This study is creating a database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information about su…

This study is creating a large, long-term database of medical information and biological samples from people with many types of cancer, those at high risk, and healthy volunteers. Researchers will use this resource to study what causes cancer, how it progresses, and how to better…

This study tests whether an AI tool can create a personalized list of questions for people with lymphoma or multiple myeloma to ask during their doctor appointments. About 40 participants will use the AI-generated list and then report how confident they felt communicating and how…

This study looks at whether CAR-T therapy, a powerful cancer treatment, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or certain lymphomas before and after CAR-T treatment to s…

This study collects blood, urine, bone marrow, and tissue samples from adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand these diseases and potentially find new ways to diagnose or treat them. No treatment is provided as pa…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues using surveys and physical tests. The goal is to better understand this group's …

This study examines how certain immune cells called monocytes influence the effectiveness of CART cell therapy in people with multiple myeloma. Researchers will analyze blood samples before and after treatment to see if monocyte levels and types can predict how well the therapy w…

This study looks at how a short-term plant-based diet or supplements (omega-3, curcumin, or probiotics) change levels of butyrate—a healthy gut compound—in people with smoldering multiple myeloma or MGUS. About 200 participants will be randomly assigned to one of the diet or supp…

This study is watching how well a combination of three drugs (selinexor, bortezomib, and dexamethasone, or SVd) works for adults with multiple myeloma who have already tried 1 to 3 other treatments. Researchers will track how long patients stay cancer-free and note any side effec…

This study is testing whether daily voice recordings from a smartphone can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for lymphoma or multiple myeloma. About 20 participants will record their voice twice a day …

This study looks at how sugar molecules attached to proteins (called N-glycosylation) might cause or worsen AL amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will analyze blood and bone marrow samples from 100 adults with related conditions to…

This study looks at how the body absorbs, breaks down, and gets rid of an experimental drug called DSP-5336. It involves 8 adults with advanced blood cancers (like leukemia or myeloma) that no longer respond to standard treatments. Participants take a single radioactive-labeled p…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancer works and why some cancers respond differently to treatment. The goal is to develop more effective …

This study looks at gene changes that might cause low blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas after CAR-T therapy. About one-third of patients have low blood counts lasting more than 30 days after treatment. Researchers will test blood a…

This study takes blood or bone marrow samples from 70 adults with multiple myeloma or acute leukemia to test a drug called Imuthiol (Zn-DDC) in the lab. Researchers want to see if Imuthiol, alone or with other drugs, can kill cancer stem cells. This is not a treatment study—it's …

This study follows 30,000 people who have early signs that may lead to multiple myeloma, a type of blood cancer. Participants have conditions like MGUS or smoldering myeloma, or have a family history of blood cancers. Researchers will track them over time to learn what factors in…

This study is gathering information from 2,000 people who are receiving a stem cell transplant for blood cancers or immune disorders. The goal is to track survival and complications over time to help doctors and researchers improve future treatments. No new drugs or procedures ar…

This study is building a registry of up to 2,000 adults with plasma cell disorders, such as multiple myeloma and amyloidosis. Participants complete health assessments and may give a blood sample to study aging markers. The goal is to gather information to support future research,…

This study aims to find out if firefighters' exposure to dangerous chemicals on the job leads to early, pre-cancerous changes in their blood that could later turn into blood cancers like leukemia or lymphoma. Researchers will enroll 300 firefighters aged 40-49 from the Charlotte …

This study is following 2,300 people in China who have various blood diseases like leukemia, multiple myeloma, and hemophilia. Researchers are collecting information from medical records to understand how common these diseases are, what treatments people receive, and how they do …

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…

This study tests whether a new radiotracer called 18F-fluciclovine can detect multiple myeloma (MM) better than the current standard tracer (18F-FDG) on PET/CT scans. About 60 adults with newly diagnosed or relapsed/refractory MM will receive both tracers and have scans compared.…

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their personal values and shares this with their doctor to guide treatment choices. Researchers want to see if using PR…

This study looks at how the blood thinner apixaban affects blood clotting in two groups: people newly diagnosed with multiple myeloma and people recovering from total knee replacement. Both groups are at high risk for dangerous blood clots. Researchers want to see if the drug wor…

This study collects and stores blood and tissue samples from 6,000 people with multiple myeloma, smoldering myeloma, plasma cell leukemia, or MGUS. Researchers will use these samples to better understand these diseases and improve future treatments. Participants provide samples a…

This study aims to understand why multiple myeloma affects African American, Latino, Asian American, and non-Hispanic White patients differently. Researchers will survey 4000 people diagnosed with multiple myeloma in California to learn about factors that may influence the diseas…

This study follows 700 people with multiple myeloma to see how cannabis (marijuana) use affects their quality of life and symptoms during chemotherapy. Researchers will compare cannabis users to non-users using surveys and medical reports. The goal is to understand potential bene…

This study is for people with advanced cancer (solid tumors, lymphoma, or multiple myeloma) that has stopped responding to standard treatments. It tests whether giving a targeted drug based on the tumor's specific gene changes can help shrink or control the cancer. The goal is to…

This study looks at a specific gene (IGLV1-44) in 100 people with AL amyloidosis, POEMS syndrome, or multiple myeloma. Researchers want to find unique features in this gene that cause these diseases. The goal is to improve early diagnosis and risk assessment, and to develop new t…

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood and solid tumors on PET/CT scans. About 30 people with non-Hodgkin lymphoma, multiple myeloma, or rare histiocytic disorders will receive the agent and then h…

This study is creating a large collection of blood, urine, and tissue samples from up to 10,000 people with amyloid diseases (like multiple myeloma). The goal is to store these samples and health data for future research to better understand these conditions. Participants do not …

This study is following 1,000 adults with early signs that can lead to multiple myeloma (a type of blood cancer). The goal is to understand why some people's condition gets worse over time while others stay stable. Researchers will use genetic testing and regular checkups to trac…

This study collects information from 1,000 people receiving stem cell transplants for blood diseases at a hospital on the Qinghai-Tibet Plateau. Researchers track recovery, complications, and costs to learn how high altitude affects treatment. The goal is to build a database that…

This study looks at whether using a simple early warning score (called NEWS) can help doctors spot when blood cancer patients on strong chemotherapy are getting sicker, and then move them to the intensive care unit (ICU) sooner. The goal is to see if this approach reduces deaths …

This study watches how older patients (60+) with certain blood cancers handle standard CAR T therapy and how it changes their daily life and thinking skills. It does not give any extra treatment. The goal is to see how many patients can complete all check-ups before their disease…

This study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma by studying families where more than one person has the disease. Researchers will collect DNA and blood samples from up to 500 participants, including patients and th…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a BMS gene-modified cell therapy (like CAR-T). Researchers will test whether the therapy's genes are present in the new tumor. The goal is to understand if the treatment played a role, …

This study is for people with MGUS or multiple myeloma who are already scheduled for a bone marrow biopsy. Researchers want to see how common sleep apnea is in these patients and whether it changes gene activity in the bone marrow. Participants provide an extra bone marrow sample…

This study enrolls 100 people with relapsed multiple myeloma to analyze their cancer's genetic makeup. Participants provide blood, cheek swab, and tumor samples during routine care. Researchers use advanced sequencing to map gene changes and identify potential new treatments. The…

This study looks at why some families have multiple members with blood cancers like lymphoma, leukemia, or myeloma. Researchers will collect genetic and lifestyle information from 3,000 participants to find links between inherited genes and cancer risk. You can join if you have a…

This study is collecting tumor samples from 300 people with high-risk blood or solid cancers, including leukemia, multiple myeloma, and pancreatic cancer. Researchers will use advanced lab tests to create a detailed profile of each tumor. The goal is to see if this information ca…